Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza; Kaleab Alemayehu Zewdie; Bekalu Amare Tesfaye; Selamawit Tesfamariam Gebrekirstos; Derbew Fikadu Berhe

doi:10.2147/DMSO.S265399

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Diabetes Metab Syndr Obes. 2020 Oct 12:13:3627-3635. doi: 10.2147/DMSO.S265399. eCollection 2020.

Authors

Muluken Altaye Ayza¹, Kaleab Alemayehu Zewdie¹, Bekalu Amare Tesfaye¹, Selamawit Tesfamariam Gebrekirstos¹, Derbew Fikadu Berhe¹

Affiliation

¹ Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia.

Abstract

Telmisartan is an angiotensin II receptor antagonist, which selectively inhibits the angiotensin II type 1 receptor. Thus, it is widely used for hypertension management. Nowadays, telmisartan's effect on peroxisome proliferator-activated receptors (PPARs) is gaining wider attention. PPARs are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Telmisartan is reported to have a partial PPARγ-agonistic effect while avoiding the safety concerns found with full PPARγ agonists (thiazolidinediones). Telmisartan could be an alternative treatment option, with dual benefit for diabetes mellitus (DM) and hypertension. This review summarizes the anti-diabetic activity of telmisartan via its partial PPARγ-agonistic activity.

Keywords: diabetes mellitus; hypertension; peroxisome proliferator-activated receptors; telmisartan.

Publication types

Review